LEASE AGREEMENTLease Agreement • August 14th, 2013 • Fate Therapeutics Inc • Biological products, (no disgnostic substances)
THIS LEASE AGREEMENT (this “Lease”) is made this 3 day of December, 2009, between ARE-3535/3565 GENERAL ATOMICS COURT, LLC, a Delaware limited liability company (“Landlord”), and FATE THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • August 14th, 2013 • Fate Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of January 5, 2009 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation and with a loan production office located at 901 Fifth Avenue, Suite 3900, Seattle, Washington 98164 (“Bank”), and FATE THERAPEUTICS, INC., a Delaware corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as follows:
ContractFate Therapeutics Inc • August 14th, 2013 • Biological products, (no disgnostic substances) • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAW OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION.
EXCLUSIVE LICENSE AGREEMENTStock Purchase Agreement • August 14th, 2013 • Fate Therapeutics Inc • Biological products, (no disgnostic substances) • California
This Exclusive License Agreement (the “Agreement”) between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and FATE THERAPEUTICS, INC. (“Fate”), a corporation having a principal place of business at 3535 General Atomics Court, Suite 200, San Diego, CA 92121, is effective on the 2nd day of May, 2013 (“Effective Date”).
EXCLUSIVE LICENSE AGREEMENT BETWEEN CHILDREN’S MEDICAL CENTER CORPORATION AND FATE THERAPEUTICS, INC.Exclusive License Agreement • August 14th, 2013 • Fate Therapeutics Inc • Biological products, (no disgnostic substances) • Massachusetts
This Agreement is made and entered into as of the date last written below (the “Effective Date”), by and between CHILDREN’S MEDICAL CENTER CORPORATION, a charitable corporation duly organized and existing under the laws of the Commonwealth of Massachusetts and having its principal office at 300 Longwood Avenue, Boston, Massachusetts, 02115, U.S.A. (hereinafter referred to as “CMCC”), and FATE THERAPEUTICS, INC., a business corporation organized and existing under the laws of the state of Delaware and having its principal office at 10931 N. Torrey Pines Rd, Suite 107, La Jolla, CA 92037, U.S.A. (hereinafter referred to as “Licensee”).
RESTATED LICENSE AGREEMENTLicense Agreement • August 14th, 2013 • Fate Therapeutics Inc • Biological products, (no disgnostic substances) • Ontario
The Ottawa Hospital Research Institute, with a business address of 725 Parkdale Avenue Ottawa, Ontario, K1Y 4E9, Canada (hereinafter “Licensor”)
Re: Fate Therapeutics, Inc. Employment AgreementEmployment Agreement • August 14th, 2013 • Fate Therapeutics Inc • Biological products, (no disgnostic substances) • California
On behalf of Fate Therapeutics, Inc. (the “Company”), I am pleased to offer you the position of the Company’s President and Chief Executive Officer (“CEO”). The terms and conditions of your employment are set forth below.
NOTE PURCHASE AGREEMENTNote Purchase Agreement • August 14th, 2013 • Fate Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
This Note Purchase Agreement (this “Agreement”) is entered into as of June 24, 2013, by and among Fate Therapeutics, Inc., a Delaware corporation (the “Company”), and the purchasers (each, an “Investor” and collectively, the “Investors”) listed on Exhibit A hereto, as amended from time to time.
FATE THERAPEUTICS, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • August 14th, 2013 • Fate Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
This Amended and Restated Investor Rights Agreement (the “Agreement”) is made as of August 8, 2013, among Fate Therapeutics, Inc., a Delaware corporation (the “Company”), the stockholders and holders of the Notes (as defined below) listed on Exhibit A hereto (each, an “Investor” and collectively, the “Investors”) and the stockholders and founders of the Company listed on Exhibit B hereto (each, a “Founder” and collectively, the “Founders”).
CONSULTING AGREEMENTConsulting Agreement • August 14th, 2013 • Fate Therapeutics Inc • Biological products, (no disgnostic substances) • California
This Consulting Agreement (this “Agreement”) is made and entered into as of December 31, 2012 by and between Fate Therapeutics, Inc., a Delaware corporation (the “Company”), and John D. Mendlein (“Consultant”).
NOTE PURCHASE AGREEMENTNote Purchase Agreement • August 14th, 2013 • Fate Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
This Note Purchase Agreement (this “Agreement”) is entered into as of August 8, 2013, by and among Fate Therapeutics, Inc., a Delaware corporation (the “Company”), and the purchasers (each, an “Investor” and collectively, the “Investors”) listed on Exhibit A hereto, as amended from time to time.
FIRST AMENDMENT TO WARRANT TO PURCHASE STOCK DATED JANUARY 5, 2009Purchase Stock Dated • August 14th, 2013 • Fate Therapeutics Inc • Biological products, (no disgnostic substances) • California
This FIRST AMENDMENT TO WARRANT TO PURCHASE STOCK DATED (this “Amendment”) is entered into this 25th day of August, 2011, by and between SVB FINANCIAL GROUP (“SVB”) and Fate Therapeutics, Inc., a Delaware corporation (“Borrower”).
SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • August 14th, 2013 • Fate Therapeutics Inc • Biological products, (no disgnostic substances)
THIS SECOND AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into this 25th day of August, 2011 by and between Silicon Valley Bank (“Bank”) and FATE THERAPEUTICS, INC., a Delaware corporation (“Borrower”) whose address is 3535 General Atomics Court, Suite 200, San Diego, CA 92121.
AMENDMENT NO. 1 TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • August 14th, 2013 • Fate Therapeutics Inc • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 1 to Loan and Security Agreement (this “Amendment”) is entered into this 4th day of May, 2010, by and between FATE THERAPEUTICS, INC., a Delaware corporation (“Borrower”) and SILICON VALLEY BANK, a California banking corporation (“SVB” or “Bank”). Capitalized terms used herein without definition shall have the same meanings given in the Loan Agreement (as defined below).
